Publisher
Peertechz Publications Private Limited
Reference35 articles.
1. 1. Donoghue M, Lemery SJ, Yuan W, He K, Sridhara R, et al. (2012) Eribulin Mesylate for the Treatment of Patients with Refractory Metastatic Breast Cancer: Use of a "Physician's Choice" Control Arm in a Randomized Approval Trial. Clin Cancer Res 18: 1496-505 .
2. 2. Shetty N, Gupta S (2014) Eribulin drug review. South Asian J Cancer 3: 57-59 .
3. 3. Smith JA, Wilson L, Azarenko O, Zhu X, Lewis BM, et al. (2010) Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability. Biochemistry 49:1331-1337 .
4. 4. Towle MJ, Salvato KA, Budrow J, Wels BF, Kuznetsov G, et al. (2001) In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogs of Halichondrin B. Cancer Res 61: 1013-1021 .
5. 5. Schöffski P, Ray-Coquard IL, Cioffi A, Bui NB, Bauer S, et al. (2011) Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes. Lancet Oncol 12: 1045-1052 .
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献